Aprea Therapeutics' Promising Cancer Drug Candidate Warrants Buy Rating
TipRanksApr 12 11:35 ET
Optimistic Outlook for Aprea Therapeutics' Oncology Pipeline: A Comprehensive Buy Rating Analysis
TipRanksApr 11 06:26 ET
Aprea Therapeutics Announces Presentations on Its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Aprea Therapeutics, Inc. (Nasdaq: APRE) today released details about four poster presentations at the ongoing American Association of Cancer Research (AACR) Annual Meeting, taking place April 5 to 10, 2024 in San Diego, CA.
GlobeNewswireApr 10 12:00 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 85.5% to $4.86 during Thursday's pre-market session. The market value of their outstanding shares is at $800.0 million. Candel Therapeutics (NASDAQ
BenzingaApr 4 08:09 ET
Aprea Therapeutics Files to Sell 4.39M Shares of Common Stock for Holders
Seeking AlphaApr 3 16:30 ET
Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating
TipRanksMar 27 16:05 ET
Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Biogen (BIIB) and Mesoblast Limited (OtherMEOBF)
TipRanksMar 27 08:20 ET
Aprea Therapeutics Is Maintained at Outperform by Wedbush
Aprea Therapeutics Is Maintained at Outperform by Wedbush
Dow JonesMar 27 08:02 ET
Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow JonesMar 26 11:22 ET
Buy Rating Affirmed: Aprea Therapeutics Poised for Growth With Strong Pipeline Momentum Into 2024
TipRanksMar 26 11:15 ET
Express News | HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Maintains $20 Price Target
Moomoo 24/7Mar 26 11:12 ET
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading
US stocks looked set to open modestly higher Tuesday as investors parsed durable goods and home price data and looked ahead to a key consumer confidence gauge. Dow Jones Industrial Average futures wer
MT NewswiresMar 26 09:29 ET
Aprea Therapeutics: Q4 Earnings Insights
Aprea Therapeutics (NASDAQ:APRE) reported its Q4 earnings results on Tuesday, March 26, 2024 at 07:45 AM.Here's what investors need to know about the announcement.EarningsAprea Therapeutics missed est
BenzingaMar 26 09:10 ET
Aprea Therapeutics GAAP EPS of -$0.92
Seeking AlphaMar 26 08:05 ET
Aprea Therapeutics 4Q Loss/Shr 92c >APRE
Aprea Therapeutics 4Q Loss/Shr 92c >APRE
Dow JonesMar 26 07:45 ET
Aprea Therapeutics: Strong Buy Rating on Robust Financials and Promising Drug Pipeline
TipRanksMar 19 15:05 ET
Karolinska Development's Portfolio Company Aprea Therapeutics Receives FDA IND Approval and Secures Funding of USD 34 Million
STOCKHOLM, SWEDEN, March 14, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has received FDA approval of the company's IND application
GlobeNewswireMar 14 07:48 ET
Aprea Therapeutics Secures Funding and Advances Drug Pipeline
TipRanksMar 12 16:43 ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersTC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 74.5% to $1.85 during Monday's pre-market session. The company's market cap stands at $4.4 million. Dyadic International (NASDAQ:DYAI) s
BenzingaMar 11 09:05 ET
Market-Moving News for March 11th
DUO: 151% | Fangdd Network shares are trading higher after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services sectorMESO: 52% | United States Food
BenzingaMar 11 08:40 ET
No Data
No Data